Timothy J Price

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Marc Peeters, Tae Won Kim, P. Ruff, 2014, The Lancet. Oncology.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Dongsheng Tu, John R Zalcberg, Lois Shepherd, 2008, The New England journal of medicine.

Management of gastric cancer in Asia: resource-stratified guidelines.

Yan-Shen Shan, Takeshi Sano, Yoon-Koo Kang, 2013, The Lancet. Oncology.

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases.

Amanda Townsend, T. Price, Timothy J Price, 2008, Archives of surgery.